Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, United States.
J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Sep 1;1125:121711. doi: 10.1016/j.jchromb.2019.121711. Epub 2019 Jul 4.
Busulfan and melphalan are cytotoxic DNA alkylating agents that are used in many hematopoietic stem cell transplantation (HCT) conditioning regimens. We report the development of an assay using turbulent flow liquid chromatography (TFLC) and tandem mass spectrometry to simultaneously measure the concentration of busulfan (Bu) and melphalan (Mel) in human plasma. The method involves precipitating proteins in the plasma specimen with an organic solvent containing deuterated internal standards of both compounds. Following centrifugation, an aliquot of the supernatant was injected into the TFLC mass spectrometry system operated in the positive ion mode. The analytical measurement range for both compounds was 10-5000 ng/mL, and with validated dilutions the reportable range was extended to 25,000 ng/mL. Intra-day and inter-day (n = 20 day) precision studies showed a coefficient of variation (CV) of <7% at several concentrations across the measurement range. To determine accuracy recovery studies were performed at several concentrations spanning the measurement range. Recoveries for both compounds were between 98 and 103%. Additionally, busulfan was compared with an existing assay and showed excellent correlation. Experiments were conducted to rule out matrix effects, carryover and interference from endogenous substances. The validated clinically reportable range (CRR) and assay precision will allow this assay to be used clinically to monitor and adjust Mel and Bu levels to ensure better therapeutic outcomes and also to support clinical trials aimed at better defining therapeutic ranges.
白消安和苯丙氨酸氮芥是细胞毒性 DNA 烷化剂,用于许多造血干细胞移植 (HCT) 预处理方案中。我们报告了一种使用湍流液相色谱 (TFLC) 和串联质谱同时测量人血浆中白消安 (Bu) 和苯丙氨酸氮芥 (Mel) 浓度的测定方法。该方法涉及用含有两种化合物氘代内标的有机溶剂沉淀血浆标本中的蛋白质。离心后,取上清液的一部分注入正离子模式下运行的 TFLC 质谱系统。两种化合物的分析测量范围均为 10-5000ng/mL,经验证稀释后,报告范围扩展至 25,000ng/mL。在日内和日间(n=20 天)精密度研究中,在整个测量范围内的几个浓度下,变异系数 (CV) <7%。为了确定准确度,在几个浓度范围内进行了回收研究。两种化合物的回收率在 98%至 103%之间。此外,白消安与现有的测定方法进行了比较,显示出极好的相关性。进行了实验以排除基质效应、携带和内源性物质的干扰。验证的临床可报告范围 (CRR) 和测定精密度将允许该测定法在临床上用于监测和调整 Mel 和 Bu 水平,以确保更好的治疗效果,并支持旨在更好地定义治疗范围的临床试验。